Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Liraglutide on Cognitive Function in Type 2 Diabetes
NCT03707171Phase 3Completed
- Sponsor
- Army Medical University
- Start
- Oct 2018
- Primary completion
- Feb 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of liraglutide in type 2 diabetes mellitus (T2DM) and cognitive dysfunction (2 arms), sponsored by Army Medical University. Primary endpoint: Changes of cognitive function assessed by cognitive function scale at 12 weeks. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)cognitive dysfunction
Beyond the preview
Go deeper on NCT03707171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03707171.